Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, Micol JB; UNIHEM, French Network of Pharmacovigilance Centers, ALFA, FILO, and GFM. Marmouset V, et al. Among authors: boyer t. Clin Cancer Res. 2022 Dec 1;28(23):5211-5220. doi: 10.1158/1078-0432.CCR-22-1622. Clin Cancer Res. 2022. PMID: 36201165
Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study.
Boyer T, Gonzales F, Barthélémy A, Marceau-Renaut A, Peyrouze P, Guihard S, Lepelley P, Plesa A, Nibourel O, Delattre C, Wetterwald M, Pottier N, Plantier I, Botton S, Dombret H, Berthon C, Preudhomme C, Roumier C, Cheok M. Boyer T, et al. Cancers (Basel). 2019 Sep 6;11(9):1323. doi: 10.3390/cancers11091323. Cancers (Basel). 2019. PMID: 31500210 Free PMC article.
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
Fenwarth L, Fournier E, Cheok M, Boyer T, Gonzales F, Castaigne S, Boissel N, Lambert J, Dombret H, Preudhomme C, Duployez N. Fenwarth L, et al. Among authors: boyer t. Int J Mol Sci. 2020 Aug 6;21(16):5626. doi: 10.3390/ijms21165626. Int J Mol Sci. 2020. PMID: 32781546 Free PMC article. Review.
Poly(ADP-ribose)polymerase inhibitors-associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres.
Morice PM, Genthon A, Boyer T, Bihan K, Mahé J, Sourisseau A, Peyrouzet H, Miremont G, Lepelley M, Stefani L, Gaboriau L, Rocher F, Aquaronne D, Le Beller C, Allouchery M, Azzouz B, Massy N, Alt-Tebacher M, Simand C, Herbrecht R, Chrétien B, Dolladille C, Chantepie S, Alexandre J. Morice PM, et al. Among authors: boyer t. Br J Haematol. 2022 Feb;196(3):787-793. doi: 10.1111/bjh.17863. Epub 2021 Oct 5. Br J Haematol. 2022. PMID: 34611896 No abstract available.
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML.
Duchmann M, Wagner-Ballon O, Boyer T, Cheok M, Fournier E, Guerin E, Fenwarth L, Badaoui B, Freynet N, Benayoun E, Lusina D, Garcia I, Gardin C, Fenaux P, Pautas C, Quesnel B, Turlure P, Terré C, Thomas X, Lambert J, Renneville A, Preudhomme C, Dombret H, Itzykson R, Cluzeau T. Duchmann M, et al. Among authors: boyer t. Leukemia. 2022 Mar;36(3):656-663. doi: 10.1038/s41375-021-01435-7. Epub 2021 Oct 6. Leukemia. 2022. PMID: 34615986 Clinical Trial.
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.
Renneville A, Abdelali RB, Chevret S, Nibourel O, Cheok M, Pautas C, Duléry R, Boyer T, Cayuela JM, Hayette S, Raffoux E, Farhat H, Boissel N, Terre C, Dombret H, Castaigne S, Preudhomme C. Renneville A, et al. Among authors: boyer t. Oncotarget. 2014 Feb 28;5(4):916-32. doi: 10.18632/oncotarget.1536. Oncotarget. 2014. PMID: 24659740 Free PMC article. Clinical Trial.
Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.
Boyer T, Guihard S, Roumier C, Peyrouze P, Gonzales F, Berthon C, Quesnel B, Preudhomme C, Behal H, Duhamel A, Roche-Lestienne C, Cheok M. Boyer T, et al. Oncotarget. 2016 Sep 20;7(38):62377-62385. doi: 10.18632/oncotarget.11481. Oncotarget. 2016. PMID: 27566555 Free PMC article.
455 results